SEATTLE--(BUSINESS WIRE)--Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, today shares with the public preliminary study results from Texas Biomedical Research Institute (Texas Biomed) indicating the Particle bulb’s ability to inactivate SARS-CoV-2, the virus that causes COVID-19. In addition, the Particle bulb can kill a number of common household bacteria and germs, for example E. Coli, Salmonella, and Staphylococcus.
Rather than using dangerous UV-C light to kill germs quickly, Particle’s method is “low and slow.” Particle bulb disinfects germs using Gentle UV, a blend of UV-A light, for longer periods, allowing it to be used safely near people in homes, businesses, and institutions.
Multiple tests performed by Texas Biomed demonstrated a 95% reduction in the SARS-CoV-2 virus after 5 hours of exposure to the Particle bulb; a 99% reduction in 6 hours; and a 99.9% reduction in 8 hours.
“We were very pleased to work with Texas Biomed because of their reputation as a global leader in eradicating infectious diseases and we’re really excited by these results,” said Know Labs CEO, Phil Bosua.
Texas Biomed is a world-renowned, independent, nonprofit biomedical research institute specializing in infectious diseases. Home to a CDC-regulated biosafety level-4 laboratory, Texas Biomed develops vaccines and therapies to successfully treat some of the world’s deadliest diseases, including COVID-19. Viraj Kulkarni, Ph.D., Staff Scientist at the Disease Intervention & Prevention Division at Texas Biomed, stated, "Study results indicated Particle bulb is effective at inactivating the virus that causes COVID-19. Technologies, like Particle, have great potential in assisting the world.”
Sign up for updates at particlebulb.com
About Texas Biomedical Research Institute
Texas Biomed is an independent, nonprofit research institute that has delivered high quality and reliable scientific data, spanning basic discovery through preclinical development. Texas Biomed performs both independent, grant-funded research and contract research, contributing to the development of diagnostics, therapies and vaccines to combat the world’s deadliest diseases.
Texas Biomed is one of the world’s leading independent biomedical research institutions dedicated to eradicating infection and advancing health worldwide through innovative biomedical research. Texas Biomed partners with researchers and institutions around the world to develop therapeutics and vaccines against viral pathogens causing AIDS, hepatitis, hemorrhagic fever, tuberculosis and parasitic diseases responsible for malaria and schistosomiasis disease. The Institute has programs in host-pathogen interaction, disease intervention and prevention and population health to understand the links between infectious diseases and other diseases such as aging, cardiovascular disease, diabetes and obesity. For more information on Texas Biomed, go to www.TxBiomed.org
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2020, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.